The mandate from EMA is that no paper submission should be submitted to any regulatory agency within EU after January 1, 2010 for the centralized Procedure that includes EMA, Rapporteurs and all CHMP members.

The Navitas pharmaREADY eSubmissions team provides extensive experience in eSubmissions consulting for any submission made in the context of a centralized application procedure and the subsequent maintenance of the lifecycle of the application including:

  • Initial application
  • Supplementary information
  • Variations
  • Renewals
  • Follow-Up Measures (FUMs)
  • Periodic Safety Update Reports (PSURS)
  • Notifications

Any eCTD submission submitted to EMA should be checked for Technical and Business Validation conformance. The Navitas pharmaREADY eSubmissions team is well versed with checking the correctness of the eCTD submission from both technical (using automated validation tools) and business perspectives (a thorough Quality Analysis performed by in-house scientific and Regulatory Affairs consultants).

Submissions Milestones

The Navitas pharmaREADY eSubmissions team can help customers to meet the key milestones as outlined below in a typical market authorization procedure.

  1. Initial submission (Day 0 of procedure)
  2. Response to business validation issues (if required)
  3. Response to List of Questions (i.e. Day 121 for a new application)
  4. Response to List of Outstanding Issues (i.e. Day 181, if required)
  5. Application as agreed at Opinion (i.e. agreed EN product information if changed at CHMP)
  6. Provision of translations (i.e. Day 215 for a new application)
  7. Provision of final agreed translations following linguistic review (it is not also required to send interim working versions of the product information before this point as eCTD)
  8. Decision (i.e. final amended documentation if any changes occur during the Standing Committee phase)

Test eCTD

The pharmaREADY eSubmissions team encourages and supports customers wanting to submit test eCTDs, particularly if the applicant has limited experience of producing eCTDs and would like to investigate particular areas of concern to ensure technical validity at the time of formal submission. The test submission process at EMA for the centralized procedure is an informal process, and the Navitas pharmaREADY eSubmissions team can provide pragmatic assistance for the applicant.

Global Submissions

The eCTD is indeed an international standard and is also implemented in the US and Canada and accepted by FDA and Health Canada. However, while one of the primary objectives of introducing the eCTD is to facilitate the preparation of applications intended for multiple regions, care must be taken over the adaptation of the submission to meet regional requirements. The Navitas pharmaREADY eSubmissions team carries credible global submission experience across different international agencies, and can help customers adapt to different regional requirements, while at the same time reducing the duplication effort and providing hands-on support.


Navitas Life Sciences announces acquisition of DataCeutics Inc to augment...

Navitas Life Sciences, a TAKE Solutions Enterprise today announced that it will be acquiring Life Sciences services...


Life Sciences expert Navitas augments end-to-end capabilities

Navitas, a technology-led Life Sciences services provider across Clinical, Regulatory and Safety, announced that it would be...


BioVectra chooses pharmaREADY for eCTD Solution

BioVectra has chosen pharmaREADY for its eCTD requirements. BioVectra, located in Canada, manufactures ingredients for global...


Navitas at DIA's 10th Annual Forum for Qualified Persons...

Navitas Principal Jeffrey Ho will present “Efficient content management for the compilation and management of the...


Navitas Celebrates 100th pharmaREADY customer

pharmaREADY is Navitas’ intuitive and easy to use, fully integrated, regulatory compliant, web-based suite comprised of modules...


Navitas Introduces Innovative Regulatory Process Outsourcing Model

The workload for regulatory functions of pharmaceutical companies has continued to increase in recent years ...